Comparative Pharmacology
Head-to-head clinical analysis: SULF 15 versus SULFAIR 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULF 15 versus SULFAIR 10.
SULF-15 vs SULFAIR 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SULF-15 is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels (K_ATP), leading to cell membrane depolarization, calcium influx, and exocytosis of insulin.
Bacteriostatic inhibitor of dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
150 mg orally twice daily for 14 days.
5 mg orally once daily, taken at bedtime.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to >30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life of 8-12 hours in adults with normal renal function (CrCl >60 mL/min); extends to 20-30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal excretion accounts for 60-70% of elimination as unchanged drug; biliary/fecal excretion accounts for 20-30% as metabolites and parent compound.
Renal excretion of unchanged drug (approximately 70-80%) and hepatic metabolism (20-30% as metabolites). Fecal elimination is minimal (<5%).
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)